 |
|
|
|
 |
|
|
|
| Article 1 to 10 out of 88
|
|
-
Biovitrum and Symphogen Initiates a Second Clinical study with a Novel Treatment of Hemolytic Diseases
(21 Apr 2008)
Biovitrum AB and Symphogen A/Sannounced the initiation of a clinical proof of mechanism study to demonstrate the ability of Sym001 (RhD polyclonal antibody) to clear RhD-positive red blood cells from the circulation of RhD-negative healthy ......
-
Pharmalink reports the approval of key patent for chemotherapy drug Busulipo
(16 Apr 2008)
Pharmalink AB announced that the U.S. Patent and Trademark Office has approved U.S. Patent No. 7,351,427, relating to the pharmaceutical composition, method of preparation and method of treatment by use of busulfan, which is the active agent in ......
-
Genentech invests in BioInvent to develop cardiovascular antibodies
(08 Apr 2008)
BioInvent has entered a strategic partnership with Genentech. Genentech has invested in BioInvent's proprietary antibody for the potential treatment of cardiovascular diseases, and will help co-develop and commercialise the product. BioInvent's ......
-
GATC Biotech opens office in Sweden
(08 Apr 2008)
GATC Biotech of Germany is to open a new office in Stockholm as part of its Scandinavian expansion drive. The new Stockholm headquarters will provide expanded sales and support services across the Scandinavian region, where the company's ......
-
First premature infant recruited in Kiobrina study
(07 Apr 2008)
Triggers milestone payment from Biovitrum
Biovitrum AB is in clinical phase II with the Kiobrina project and the first preterm infant has been recruited. This triggers a milestone payment from Biovitrum. Kiobrina(TM) is a recombinant, biotechnically produced human enzyme (BSSL) that ......
-
Eisai invests in BioArctic's Alzheimer research
(07 Apr 2008)
Japanese firm inputs world-leading know-how in next-generation treatment
Eisai Co. Ltd has signed an exclusive licence agreement with Uppsala-based biopharmaceutical company BioArctic Neuroscience for their monoclonal antibody BAN2401, developed as a next-generation treatment for Alzheimer's Disease. The amount ......
-
Newly Discovered Protein Inhibits the Formation of the Precursor to Alzheimer's Plaques
(31 Mar 2008)
Unexpected Discovery Made by Swedish Researchers within the Field of Alzheimer
As of today, there is no cure or effective treatment of Alzheimer's disease. Swedish researchers have now through their discoveries opened up new possible strategies for potential treatment of the actual cause of the disease. These results have ......
-
BioInvent signs deal with Bayer HealthCare for the discovery and development of therapeutic antibodies
(13 Mar 2008)
BioInvent International AB (OMXS: BINV) announced that it has signed a deal with Bayer HealthCare related to the discovery and development of antibody products. Under the terms of the agreement, Bayer HealthCare will have a non-exclusive ......
-
Biotage AB Increases Focus on Environmental Market Segments
(21 Feb 2008)
Biotage AB announced plans to increase its focus on growing business opportunities in the environmental analysis business. The strategy includes redeployed marketing and sales resources along with new product development for specific ......
-
Biovitrum has Completed an Exploratory Clinical Phase II Study in Glaucoma
(15 Feb 2008)
Biovitrum has completed a first explorative clinical Phase II study with the candidate drug BVT.28949, a 5-HT2A antagonist intended for the treatment of glaucoma. The preliminary results show a dose dependent reduction of the intraocular ......
|
|
|
Top